If you have been reading about circadian clock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Pickens reprised the role in two episodes of the 10th season revival and currently (2019) appears on a recurring basis on The Conners. Mr. Parkin (Stan Freberg) – A highly qualified man who is frequently unemployed due to various incidents with the Conners. Scott (Fred Willard) – A probate attorney who marries Leon. Stinky (Matthew Fishman) – Roseanne's youngest child in an alternate reality, in the place of Jerry. Ziggy (Jay O. Sanders) – An old friend of the Conners. Roseanne reveals that his real name is Norbert, then asks, "does your mom still call you Norbie?" Ziggy helps Dan open Lanford Custom Cycle, then disappears. Jimmy Gartner (Danny Masterson) – Darlene's boyfriend, for whom she breaks up with David. In the 16th episode of season 7, Darlene confesses to Jackie that he broke up with her because he could not get close to her. Ronnie (Joan Collins) – Roseanne's rich cousin who persuades Darlene to get her GED and apply to art school.
Archival Resources Details Thorburn Brailsford Robertson: Repository: Commonwealth Scientific and Industrial Research Organisation (CSIRO) Corporate Records and Archives Strategies, The Encyclopedia of Australian Science and Innovation. Robertson, Thorburn Brailsford (1884–1930), The Encyclopedia of Australian Science and Innovation. Thorburn Brailsford Robertson, Adelaide Connect, University of Adelaide. Lehmann Jayne, "World Diabetes Day – Time to celebrate Adelaide’s link to 1922 insulin discovery", EdHealth Australia, 14 November 2016. Thorburn Brailsford Robertson, South Australian Medical Heritage Society. TROVE: "From the library of Thorburn Brailsford Robertson".
ATC code H01 Pituitary and hypothalamic hormones and analogues is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup H01 is part of the anatomical group H Systemic hormonal preparations, excluding sex hormones and insulins. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QH01. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. H01AA01 Corticotropin H01AA02 Tetracosactide H01AB01 Thyrotropin alfa H01AC01 Somatropin H01AC02 Somatrem H01AC03 Mecasermin H01AC04 Sermorelin H01AC05 Mecasermin rinfabate H01AC06 Tesamorelin H01AC07 Somapacitan H01AC08 Somatrogon H01AC09 Lonapegsomatropin H01AX01 Pegvisomant QH01AX90 Capromorelin
=== Nuclear weapons === Neptunium is fissionable, and could theoretically be used as fuel in a fast-neutron reactor or a nuclear weapon, with a critical mass of around 60 kilograms. In 1992, the U.S. Department of Energy declassified the statement that neptunium-237 "can be used for a nuclear explosive device". It is not believed that an actual weapon has ever been constructed using neptunium. As of 2009, the world production of neptunium-237 by commercial power reactors was over 1000 critical masses a year, but to extract the isotope from irradiated fuel elements would be a major industrial undertaking. In September 2002, researchers at the Los Alamos National Laboratory briefly produced the first known nuclear critical mass using a significant fraction of neptunium, in combination with shells of enriched uranium (uranium-235), discovering that the critical mass of a bare sphere of neptunium-237 "ranges from kilogram weights in the high fifties to low sixties", showing that it "is about as good a bomb material as [uranium-235]". The United States Federal government made plans in March 2004 to move America's supply of separated neptunium to a nuclear-waste disposal site in Nevada.
Sources: en.wikipedia.org
There are 20 naturally occurring amino acids, however some of these share similar characteristics. For example, leucine and isoleucine are both aliphatic, branched hydrophobes. Similarly, aspartic acid and glutamic acid are both small, negatively charged residues. Although there are many ways to classify amino acids, they are often sorted into six main classes on the basis of their structure and the general chemical characteristics of their side chains (R groups).
Thickening foliage provided the insurgents with concealment from South African patrols, and their tracks were obliterated by the rain. At the end of April or early May, PLAN cadres returned to Angola to escape renewed SADF search and destroy efforts and retrain for the following year. Another significant factor of the physical environment was South West Africa's limited road network. The main arteries for SADF bases on the border were two highways leading west to Ruacana and north to Oshikango, and a third which stretched from Grootfontein through Kavangoland to Rundu. Much of this vital road infrastructure was vulnerable to guerrilla sabotage: innumerable road culverts and bridges were blown up and rebuilt multiple times over the course of the war. After their destruction PLAN saboteurs sowed the surrounding area with land mines to catch the South African engineers sent to repair them. One of the most routine tasks for local sector troops was a morning patrol along their assigned stretch of highway to check for mines or overnight sabotage. Despite their efforts, it was nearly impossible to guard or patrol the almost limitless number of vulnerable points on the road network, and losses from mines mounted steadily; for instance, in 1977 the SADF suffered 16 deaths due to mined roads. Aside from road sabotage, the SADF was also forced to contend with regular ambushes of both military and civilian traffic throughout Ovamboland.
negative control Also negative regulation. The inhibition or deactivation of some biological process caused by the presence of a specific molecular entity (e.g. a repressor), in the absence of which the process is not inhibited and thus can proceed normally. In gene regulation, for example, a repressor may bind to an operator upstream from a coding sequence and prevent access by transcription factors and/or RNA polymerase, thereby blocking the gene's transcription. This is contrasted with positive control, in which the presence of an inducer is necessary to switch on transcription.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.